Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes

Alhadj Ali, Mohammad; Liu, YF; Arif, Sefina; Tatović, Danijela; Shariff, Hina; B. Gibson, Vivienne; Yusuf, Norkhairin; Baptista, Roman; Eichmann, Martin; Petrov, Nedyalko; Heck, Susanne; H. M. Yang, Jennie; Tree, Timothy; Pujol‐Autonell, Irma; Yeo, Lorraine; Baumard, Lucas; Stenson, Rachel; Howell, A; Clark, A.G.; Boult, Zoe; Powrie, Jake; Adams, Laura; Susan Wong, F.; D. Luzio, Stephen; Dunseath, Gareth; Green, Kate; O’Keefe, Alison; Bayly, Graham; Thorogood, Natasha; Andrews, Robert; Leech, Nicola; Joseph, Frank; Nair, Sunil; T. Seal, Susan; Cheung, HoYee; A. Beam, Craig; K. Hills, Robert; Peakman, Mark; Dayan, Colin

doi:10.1126/scitranslmed.aaf7779

Public

Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes

Published in Science Translational Medicine • Aug 9, 2017

Authors:

Mohammad Alhadj Ali

YF Liu

Sefina Arif

Abstract

)-restricted immunodominant proinsulin peptide intradermally every 2 or 4 weeks for 6 months in newly diagnosed type 1 diabetes patients. Treatment was well tolerated with no systemic or local hypersensitivity. Placebo subjects showed a significant decline in stimulated C-peptide (measuring insulin ...

Subject

Proinsulin

Medicine

Immune system

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!